Evidence map›Paper›PMID 32486488›Full record

ReviewNutrients2020

Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.

Mario Mehmel, Nina Jovanović, Urs Spitz

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 128 papers.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05561738 naterminatednot on this mapstarted 2024, after this paper: background citation

Nicotinamide Riboside in Ulcerative Colitis

TypeinterventionalSponsorUniversity of PittsburghRan2024 to 2026Enrolled19ConditionsUlcerative ColitisArmsNicotinamide Riboside Chloride, Placebo, Standard of Care
NCT06991712 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Comparisons of Nicotinamide Adenine Dinucleotide (NAD) Precursors for Neuroenhancement in Glaucoma Patients

TypeinterventionalSponsorChristopher Kai Shun LeungRan2025 to 2026Enrolled138ConditionsGlaucomaArmsNicotinamide Riboside, Nicotinamide, Nicotinamide Mononucleotide, Nicotinic Acid, Placebo (Corn Starch)
3 · Its place in the literature

Who cites it

128 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. NADAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. RestorinDrug design, development and therapy · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mario MehmelBiosynth Carbosynth, Rietlistrasse 4, 9422 Staad, Switzerland.
Nina JovanovićFaculty of Biology, Department of Biochemistry and Molecular Biology, Institute of Physiology and Biochemistry, University of Belgrade, Studentski Trg 1, 11000 Belgrade, Serbia.
Urs SpitzBiosynth Carbosynth, Axis House, High Street, Compton, Berkshire RG20 6NL, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nicotinamide riboside (NR) has recently become one of the most studied nicotinamide adenine dinucleotide (NAD

Indexed as

Dietary SupplementsAgingAnimalsBetacoronavirusBiological AvailabilityCardiovascular DiseasesCoronavirus InfectionsCOVID-19HumansLongevityMetabolismNeurodegenerative DiseasesNiacinamidePandemicsPneumonia, ViralPyridinium CompoundsNiacinamidenicotinamide-beta-ribosidePyridinium Compoundsage-associated diseasesbioavailabilityCOVID-19metabolic disordersnicotinamide adenine dinucleotidenicotinamide ribosidesafetysupplementation

Identifiers

PMID32486488
PMCPMC7352172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.